Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Related to this article
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement
Trending on Urology Times
1
Carotuximab plus apalutamide shows interim PFS benefit in mCRPC
2
Altaviva™ Tibial Implant Is Reshaping UUI Therapy
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5